Dr Lal Pathlabs (LALPATHLAB)

FairStock Score: 62/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Excellent profitability with ROE of 24.32% and ROCE of 28.88%.
• Very low leverage at 0.07 Debt/Equity; Altman Z-Score of 7.88 indicates strong financial stability.
• Robust fundamental health evidenced by Piotroski F-Score of 8/9.
• Healthy free cash flow of ₹266 Cr and latest quarter net profit of ₹91 Cr on sales of ₹660 Cr.
• High promoter holding of 53.21% aligns management with shareholders.

Concerns

• Valuation is rich: P/E of 42.75 and P/B of 11.04, with price far above Graham Number of ₹303.93 and DCF value of ₹408.93.
• Margin of safety is deeply negative at -360.6%, leaving little room for error.
• Revenue growth is moderate at 10.76% latest and 9.25% 5-year CAGR; PEG of 3.14 suggests the market has overpaid for growth.
• Negative EV/EBITDA of -48.64 is an anomaly that would require deeper investigation before relying on multiples.

AI Analysis

Let's look at Dr Lal Pathlabs as a business first. It has the signature of a good compounder: 24.32% ROE, 28.88% ROCE, almost no debt at 0.07 Debt/Equity, and a strong 8/9 Piotroski score. The latest quarter adds to the picture with ₹660 Cr in sales and ₹91 Cr in net profit, and free cash flow of ₹266 Cr tells me earnings are being converted into cash. Promoters own 53.21%, which aligns their interests with mine as a minority shareholder. The high returns on capital and steady demand for diagnostics suggest an enduring franchise, though I must be honest: the table alone doesn't fully reveal the moat's source. At ₹1431.05, however, the market is asking a great deal. The P/E of 42.75 and P/B of 11.04 are far above what Graham would call a reasonable price. Graham Number is ₹303.93 and a conservative DCF gives ₹408.93; buying today gives me a margin of safety of -360.6%, meaning I am paying for perfection. Revenue growth has been modest: 5-year CAGR of 9.25% and latest sales growth of 10.76%. Profit growth of 26.75% is encouraging, but a PEG of 3.14 suggests most of that improvement is already in the price. The dividend yield of 0.86% is hardly a cushion. Would I buy? Not at this price. This is a good business, but a poor investment at today's quote. I would put it on my watchlist and wait for Mr. Market to offer a more rational valuation.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer